SCHEMBL15569849

SCHEMBL15569849

Nc1ccc2[nH]c(-c3ccncc3)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.60
ALDH1A1 P00352 8/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
PKN1 Q16512 3/20 0.60
PKN2 Q16513 3/20 0.60
RXFP1 Q9HBX9 2/20 0.60
CACNA1B Q00975 1/20 0.60
APBA1 Q02410 1/20 0.60
HPGD P15428 6/20 0.59
HSD17B10 Q99714 5/20 0.59
CYP3A4 P08684 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
RHEB Q15382 1/20 0.59
MAPT P10636 7/20 0.58
SMN1; SMN2 Q16637 7/20 0.58
NPC1 O15118 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30343722 1.00 KDM4E (0.60) KDM4EALDH1A1MEN1KMT2APKN1
SCHEMBL30533210 0.90 MEN1 (0.73) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL1655753 0.90 MEN1 (0.73) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL6263502 0.89 ALDH1A1 (0.58) KDM4EALDH1A1MEN1KMT2APKN1
SCHEMBL22906080 0.89 ALDH1A1 (0.58) KDM4EALDH1A1MEN1KMT2APKN1
SCHEMBL30307784 0.88 ALDH1A1 (0.74) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL28312335 0.88 ALDH1A1 (0.74) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL159873 0.88 ALDH1A1 (0.74) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL8769051 0.88 MEN1 (0.71) KDM4EALDH1A1MEN1KMT2ARXFP1
SCHEMBL23999512 0.87 MEN1 (0.54) KDM4EALDH1A1MEN1KMT2APKN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2025-12-30 US disclosed
EP-3515904-B1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2024-01-17 EP disclosed
CN-110234640-B Benzimidazole derivatives as anticancer agents 利昂贝拉尔中心 2023-04-07 CN disclosed
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents CENTRE LEON BERARD (FR) 2022-11-03 US disclosed
US-11384081-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2022-07-12 US disclosed
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2021-09-23 US disclosed
CN-110234640-A Benzimidazole derivatives as anticancer agents 利昂贝拉尔中心 2019-09-13 CN disclosed
EP-3515904-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS Centre Leon Berard (FR) 2019-07-31 EP disclosed
WO-2018054989-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2018-03-29 WO disclosed
US-9447134-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2016-09-20 US disclosed
US-9447134-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2016-09-20 US disclosed
US-20150210727-A1 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-07-30 US disclosed
US-20150210727-A1 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-07-30 US disclosed
WO-2014028931-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS BRANDEIS UNIVERSITY (US) 2014-02-20 WO disclosed
WO-2014028931-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS BRANDEIS UNIVERSITY (US) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CCAR2, MAPKAP1, BCOR KDM4E 4285/4885ALDH1A1 3500/4885MEN1 4170/4885
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS TMBIM6, BAX, MAPK14 KDM4E 1838/4885ALDH1A1 2866/4885MEN1 4272/4885
US-11384081-B2 Benzoimidazole derivatives as anticancer agents TMBIM6, BAX, MAPK14 KDM4E 1838/4885ALDH1A1 2866/4885MEN1 4272/4885
US-20150210727-A1 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS IMPDH1, IMPDH2, IMPA1 KDM4E 2734/4885ALDH1A1 57/4885MEN1 3865/4885
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents TMBIM6, BAX, BCL2 KDM4E 1858/4885ALDH1A1 2871/4885MEN1 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.